The Cancer Letter

Inside information on cancer research and drug development

In Brief

FDA seeks $8.4B to further investments in public health programs, including $20M for Cancer Moonshot efforts

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
DOWNLOAD PDFTABLE OF CONTENTS

FDA is requesting a total budget of $8.4 billion as part of the president’s fiscal year 2023 budget—a nearly 34% ($2.1 billion) increase over the agency’s FY 2022 appropriated funding level—for investments in critical public health modernization, core food safety and medical product safety programs, and other public health infrastructure. 

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

In Brief

President’s Cancer Panel urges enhanced patient navigation through technology to improve health equity

The President’s Cancer Panel released a report, Enhancing Patient Navigation with Technology to Improve Equity in Cancer Care, as part of a White House event acknowledging advancements in navigation support for cancer patients over the past year. The report calls on healthcare organizations, policymakers, and technology developers to keep pace with the rapid advancement and adoption of new technology.
Drugs & Targets

FDA approves new alternative standard related to mammography report assessments

FDA recently approved Alternative Standard #25 related to the Mammography Quality Standards Act. Alternative Standard #25 allows the interpreting physician to provide an assessment of “Incomplete: Need additional imaging evaluation” for the follow-up report issued within 30 calendar days of an initial report that received an assessment of “Incomplete: Need prior mammograms for comparison.”
Table of Contents

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login

Site license subscribers:
Log in with your IP | Register a sponsored account